Our team at IBT Bioservices has extensive experience in preclinical testing services to assess the viability and effectiveness of novel therapies against respiratory illnesses such as RSV, influenza, SARS-CoV-2


Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It is a novel coronavirus that was first identified in December 2019.


The primary mode of transmission is through respiratory droplets produced when an infected person talks, coughs, or sneezes. The virus can also spread through close contact with infected individuals and by touching surfaces contaminated with the virus and then touching the face.


COVID-19 symptoms can vary widely and may include fever, cough, shortness of breath, fatigue, muscle or body aches, loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, and diarrhea. Some individuals may remain asymptomatic.


SARS-CoV-2 belongs to the Coronaviridae family. Coronaviruses are a large family of viruses that can infect various animals and humans.

IBT Bioservices has developed an extensive assortment of reagents to facilitate the advancement of therapeutics and assay development, thus supporting the progress of research on respiratory viruses.We offers a diverse array of products and services designed to facilitate respiratory virus research, ranging from viral proteins to antiserum and antibodies.



Purified monoclonal and polyclonal antibodies

Recombinant proteins

Rest assured, our reagents are of exceptional quality, and they are available for purchase to support your research endeavors.

Our preclinical testing services for SARS-CoV2 encompass a wide range of assessments, including:


Using advanced cellular and molecular techniques, we evaluate the antiviral activity of potential drugs and neutralizing activity of vaccines against SARS-CoV-2 and its variants. These studies help identify compounds that can effectively inhibit viral replication, reduce viral load, and prevent viral entry into host cells. We investigate the mechanism of action of potential treatments and vaccines, providing valuable insights into their ability to combat the virus and its emerging variants

Regulatory Support

Our team assists in compiling and organizing preclinical data required for regulatory submissions, helping streamline the approval process and facilitating the transition from preclinical to clinical trials.


Our experienced researchers utilize appropriate animal models, such as mice, ferrets, or nonhuman primates, to mimic SARS-CoV-2 infection and assess the safety and efficacy of potential treatments and vaccines. We closely monitor key parameters, including viral load, immune response, disease progression, lung pathology, and overall survival, to evaluate the effectiveness of the tested interventions. Our in vivo studies provide critical data on the treatment or vaccine's ability to control viral replication, reduce disease severity, and enhance host immune responses.

The variants we work with include, but are not limited to:

    1. Wild Type
    2. D614G Single AA Mutant
    3. Alpha (B.1.1.7)
    4. (B.1.1.207)
    5. (B.1.1.298)
    6. (B.1.2)
    7. (B.1.258)
    8. Beta (B.1.351)
    9. Epsilon (B.1.429)
    10. (B.1.494)
    11. Gamma (P.1)
    12. Kappa (B.1.617.1)
    13. Eta (B.1.525)
    14. Epsilon (B.1.427/429)
    15. Delta (B.1.617.2)
    16. Delta Plus (AY.2)
    17. Lambda (C.37)
    18. Mu (B.1.621)
    19. Delta Plus (AY4.2)
    20. Omicron(B.1.1.529)
    21. BA.2
  1. AY.4/BA.1
  2. BA.4 and BA.5 (Share the Same Spike Mutations)
  3. BA.2.12.1
  4. BA.2.75
  5. BA.4.6
  6. BQ.1
  7. BQ.1.1
  8. XBB.1
  9. XBB.1.5
  10. XBB.1.16
  11. XBB.1.9.1
  12. Wild Type
  13. D614G Single AA Mutant
  14. Alpha (B.1.1.7)
  15. (B.1.1.207)
  16. (B.1.1.298)
  17. (B.1.2)
  18. (B.1.258)
  19. Beta (B.1.351)
  20. Epsilon (B.1.429)
  21. (B.1.494)
  1. Gamma (P.1)
  2. Kappa (B.1.617.1)
  3. Eta (B.1.525)
  4. Epsilon (B.1.427/429)
  5. Delta (B.1.617.2)
  6. Delta Plus (AY.2)
  7. Lambda (C.37)
  8. Mu (B.1.621)
  9. Delta Plus (AY4.2)
  10. Omicron (B.1.1.529)
  11. BA.2
  12. AY.4/BA.1
  13. BA.4 and BA.5 (Share the Same Spike Mutations)
  14. BA.2.12.1
  15. BA.2.75
  16. BA.4.6
  17. BQ.1
  18. BQ.1.1
  19. XBB.1
  20. XBB.1.5
  21. XBB.1.16
  22. XBB.1.9.1

At IBT, we are dedicated to advancing the field of COVID-19 research and development through reliable and accurate in vitro and in vivo preclinical testing services. Our commitment to scientific excellence, ethical practices, and adherence to regulatory guidelines positions us as a trusted partner in the fight against this ongoing pandemic and its evolving variants.Contact us today to learn more about how our preclinical testing services can accelerate the development of promising treatments and vaccines for SARS-CoV-2 and its variants.